{
    "clinical_study": {
        "@rank": "28461", 
        "arm_group": [
            {
                "arm_group_label": "Multidose Vial Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL"
            }, 
            {
                "arm_group_label": "Single-Dose Syringe Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare the immune responses of the infants who have been given 13vPnC in\n      the mutidose vial formulation to the immune reponses of the infants who have been given\n      13vPnC in the single-dose syringe formulation.\n\n      It will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all\n      infants who are vaccinated."
        }, 
        "brief_title": "13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pneumococcal Vaccines", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 42 to 70 days at enrollment.\n\n          -  Determined by medical history, physical examination, and clinical judgment to be\n             eligible for the study\n\n          -  Weight of 3.5 kg or greater at the time of enrollment\n\n        Exclusion Criteria:\n\n          -  Previous vaccination with licensed or investigational pneumococcal vaccine.\n\n          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.\n\n          -  Contraindication to vaccination with pneumococcal conjugate vaccine.\n\n          -  Receipt of blood products or gamma-globulin since birth"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Days", 
            "minimum_age": "42 Days"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964716", 
            "org_study_id": "B4671001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Multidose Vial Group", 
                "description": "Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.", 
                "intervention_name": "13-valent pneumococcal conjugate vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Single-Dose Syringe Group", 
                "description": "Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.", 
                "intervention_name": "13-valent pneumococcal conjugate vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prevenar 13", 
            "13vPnC", 
            "Healthy Subjects"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4671001&StudyName=13vPnC%20Multidose%20Vial%20Safety%2C%20Tolerability%20and%20Immunogenicity%20Study%20in%20Healthy%20Infants."
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fajara", 
                        "country": "Gambia", 
                        "state": "The Gambia, West Africa", 
                        "zip": "000273"
                    }, 
                    "name": "Medical Research Council Unit, The Gambia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ksmd", 
                        "country": "Gambia", 
                        "state": "The Gambia"
                    }, 
                    "name": "Fajikunda Major Health Centre"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Gambia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Formulated in Multi-dose Vials Given With Routine Pediatric Vaccinations in Healthy Infants", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The percentage of subjects achieving a serotype-specific IgG antibody concentration \u22650.35 \u00b5g/mL for each of the pneumococcal serotypes measured 1 month after the infant series for each vaccine group.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 20 weeks of age"
            }, 
            {
                "measure": "The serotype-specific IgG geometric mean concentration (GMC) for each of the pneumococcal serotypes measured 1 month after the infant series for each vaccine group (MDV group or SDS group).", 
                "safety_issue": "No", 
                "time_frame": "Approximately 20 weeks of age"
            }, 
            {
                "measure": "The number of subjects reporting local reactions and systemic events in the 5 days after each vaccination in the multidose-vial group and in the single-dose-syringe group.", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 8 weeks, 12 weeks and 16 weeks of age"
            }, 
            {
                "measure": "The number of subjects reporting AEs in the multidose-vial group and in the single-dose-syringe group.", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 8 weeks, 12 weeks , 16 weeks and 20 weeks of age"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964716"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects in a subset achieving a serotype-specific OPA titer \u2265 lower limit of quantitation (LLOQ) for each of the pneumococcal serotypes measured 1 month after the infant series for each vaccine group.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 20 weeks of age"
            }, 
            {
                "measure": "The serotype-specific OPA geometric mean titer (GMT) for each of the pneumococcal serotypes 1 month after the infant series for each vaccine group.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 20 weeks of age"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}